Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo. The company researches, develops, manufactures and markets prescription medicines, with a focus on neurology, oncology and treatments for dementia. Eisai also develops selected medicines for areas including sleep disorders, epilepsy and gastrointestinal conditions.
Its products include Leqembi (lecanemab), a treatment for early Alzheimer’s disease developed in collaboration with Biogen, as well as Aricept (donepezil), Fycompa (perampanel), Dayvigo (lemborexant), Halaven (eribulin) and Lenvima (lenvatinib), which was developed with Merck in certain markets. The company also provides medicines and supportive therapies for cancer and other serious diseases.
Eisai traces its origins to the establishment of Nihon Eisai Co., Ltd. in 1936 and has expanded into an international pharmaceutical business serving patients and healthcare providers across Japan, the Americas, Europe and Asia. Its operations include drug discovery, clinical development, manufacturing and commercialization, supported by collaborations with other pharmaceutical companies and research organizations.
AI Generated. May Contain Errors.
Free ESALY Stock Alerts